<DOC>
	<DOCNO>NCT00548613</DOCNO>
	<brief_summary>The purpose research study determine transplant combination stem cell , obtain bone marrow patient , effective utilization rescue infarcted myocardium . End point assessment development mature stable new blood vessel well improvement cardiac function . This , Phase I , single center , prospective , non-randomized , open-label study evaluate safety feasibility use propose combination autologous stem cell . Potential subject fulfill clinical laboratory entry criterion screen undergo process bone marrow aspiration preparation two type bone marrow-derived stem /progenitor cell use . The two bone marrow-derived cell type mixed implanted patient approximately 2 week bone marrow aspiration . After transplant , patient 3 month follow-up evaluate safety well functional heart improvement analysis symptom , myocardial perfusion SPECT , echocardiography . Study population include adult male female subject , age 18-70 , present acute myocardial infarction subject recent ( within 12 month ) myocardial infarction undergo coronary artery bypass grafting . Patients divide two group : - first group enroll patient acute myocardial infarction percutaneous coronary intervention restore myocardial flow 4 hour great initiation symptom , - second group enroll patient candidate coronary artery bypass surgery myocardial infarction past 12 month . Patients receive cell mixture intracoronary intramyocardial infusion , respectively . The rationale clinical study base observation attempt use adult stem cell myocardial regeneration utilize source bone marrow derive progenitor cell potential generate new blood vessel thus contribute revascularization ischemic tissue . This therapy seem adequate sufficient , since lack source stem cell capable differentiate mature cardiac muscle cell , thus contribute recovery local contractility . The propose combination stem/progenitor cell therapy use protocol aim contribute cell type capable regenerate blood vessel muscle tissue damage MI .</brief_summary>
	<brief_title>Combination Stem Cell ( MESENDO ) Therapy Utilization Rescue Infarcted Myocardium</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<criteria>ARM : A Patients acute myocardial infarction ST elevation underwent percutaneous revascularization 4 24 hour initiation symptom . 1 . Able give write informed consent 2 . Age : 18 70 year 3 . Gender : Male Female 4 . Acute myocardial infarction occur within 424 hour onset symptom document least one following : 1 . ST Segment elevation great 2mm two consecutive lead 2 . New Bundle Branch Block symptom consistent MI 3 . Troponin I great 2.0 ng/ml ( Normal Range 0 1.5 ng/ml ) 4 . Totally occluded artery visualize angiography ARM B Patients candidate coronary artery bypass grafting surgery accord ACC/AHA guideline myocardial infarction past 12 month . 1 . Able give write informed consent 2 . Patients coronary artery disease need coronary artery bypass surgery accord ACC/AHA guideline 3 . Patients Left Ventricular Ejection Fraction £ 40 % . 4 . NYHA symptom Class II ( dyspnea moderate effort ) 5 . Defined region myocardial dysfunction relate previous myocardial infarction ( within past 12 month ) involve anterior , lateral , posterior inferior wall either following : echocardiography , ventriculography , MRI , SPECT . 6 . Age : 18 70 year 7 . Gender : Male Female ARM A 1 . Pregnancy 2 . Previous angiogenic therapy myocardial laser therapy 3 . History cancer within 5 year 4 . Known sensitivity gentamycin and/or amphotericin B 5 . Use expect use antineoplastic drug 6 . No informed consent unable provide inform consent . 7 . Any illness , Investigator 's judgment , interfere patient 's ability comply protocol , compromise patient 's safety , interfere interpretation study result . 8 . Any illness might affect patient 's survival study followup period 9 . History skeletal muscle disease , either primary ( i.e. , myopathy ) secondary ( i.e. , ischemic ) underlie myopathy myasthenia gravis , muscular dystrophy , etc . 10 . Patients active infectious disease and/or know test positive HIV , HTLV , HBVsAg , HCV , CMV and/or syphilis 11 . Cardiogenic shock severe compromise leave ventricular systolic function define ejection fraction lower 20 % . 12 . History intolerance amiodarone . 13 . End stage renal disease 14 . Contraindication MRI 15 . Any significant laboratory abnormality investigator 's opinion interfere patient 's ability comply protocol , compromise patient 's safety , interfere interpretation study result . 16 . Inability identify infarct area intra operatively ARM B 1 . Previous angiogenic therapy myocardial laser therapy 2 . History cancer within 5 year 3 . Cardiogenic shock severe compromise leave ventricular systolic function define ejection fraction lower 20 % . 4 . Left Ventricular Ejection Fraction ≥ 40 % . 5 . Known sensitivity gentamycin and/or amphotericin B 6 . Use expect use antineoplastic drug 7 . No informed consent unable provide inform consent 8 . Any illness , Investigator 's judgment , interfere patient 's ability comply protocol , compromise patient safety , interfere interpretation study result 9 . Any illness might affect patient 's survival study followup period 10 . History skeletal muscle disease , either primary ( i.e. , myopathy ) secondary ( i.e. , ischemic ) underlie myopathy myasthenia gravis , muscular dystrophy , etc . 11 . Patients active infectious disease and/or know test positive HIV , HTLV , HBVsAg , HCV , CMV and/or syphilis 12 . Poor candidate coronary artery bypass surgery 13 . Patients need emergency bypass surgery 14 . History prior coronary artery bypass surgery 15 . Patients severe valvular heart disease 16 . History intolerance amiodarone 17 . End stage renal disease 18 . Pregnancy 19 . Contraindication MRI 20 . Any significant laboratory abnormality investigator 's opinion interfere patient 's ability comply protocol , compromise patient 's safety , interfere interpretation study result . 21 . Inability identify infarct area intra operatively .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Heart Attack</keyword>
	<keyword>Coronary Artery Bypass Grafting</keyword>
</DOC>